These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 35234552)
21. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Saracco GM; Morino M; Astegiano M Rev Esp Enferm Dig; 2020 Mar; 112(3):195-200. PubMed ID: 32054272 [TBL] [Abstract][Full Text] [Related]
22. The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5. Bouhnik Y; Carbonnel F; Fumery M; Flamant M; Buisson A; Camoin A; Addison J Dig Liver Dis; 2023 Dec; 55(12):1658-1666. PubMed ID: 37308394 [TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial. Hanauer S; Liedert B; Balser S; Brockstedt E; Moschetti V; Schreiber S Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):816-825. PubMed ID: 34388360 [TBL] [Abstract][Full Text] [Related]
24. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421 [TBL] [Abstract][Full Text] [Related]
25. Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases. Kay J; Cross RK; Feldman SR; Park Y; Hanauer SB Adv Ther; 2024 Feb; 41(2):509-533. PubMed ID: 38110655 [TBL] [Abstract][Full Text] [Related]
26. Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa. Ricceri F; Rosi E; Di Cesare A; Pescitelli L; Fastame MT; Prignano F Dermatol Ther; 2020 Nov; 33(6):e14387. PubMed ID: 33030281 [TBL] [Abstract][Full Text] [Related]
27. Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. Bruni C; Gentileschi S; Pacini G; Bardelli M; Tofani L; Bartoli F; Baldi C; Cometi L; Fiori G; Nacci F; Cantarini L; Guiducci S; Moggi-Pignone A; Frediani B; Matucci-Cerinic M Ther Adv Musculoskelet Dis; 2021; 13():1759720X211033679. PubMed ID: 35116080 [TBL] [Abstract][Full Text] [Related]
28. Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease. Kaniewska M; Rosołowski M; Rydzewska G Pol Arch Intern Med; 2019 Aug; 129(7-8):484-489. PubMed ID: 31316042 [TBL] [Abstract][Full Text] [Related]
29. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study. Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624 [TBL] [Abstract][Full Text] [Related]
30. Adalimumab versus ustekinumab as first-line biological in moderate-to-severe Crohn's disease: real-life cohort from a tertiary referral center. Moens A; Alsoud D; Verstockt B; Sabino J; Ferrante M; Vermeire S Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1015-1020. PubMed ID: 36062494 [TBL] [Abstract][Full Text] [Related]
31. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness? Roccuzzo G; Rozzo G; Burzi L; Repetto F; Dapavo P; Ribero S; Quaglino P Dermatol Ther; 2022 Nov; 35(11):e15803. PubMed ID: 36062429 [TBL] [Abstract][Full Text] [Related]
32. Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study. Feldman SR; Reznichenko N; Pulka G; Kingo K; George Galdava ; Berti F; Sobierska J; Dias R; Guenzi E; Hendrik Otto ; Haliduola HN; Kay R; Stroissnig H BioDrugs; 2021 Nov; 35(6):735-748. PubMed ID: 34657274 [TBL] [Abstract][Full Text] [Related]
33. Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty-Two-Week Phase III Randomized Study Results. Weinblatt ME; Baranauskaite A; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Baek I; Ghil J Arthritis Rheumatol; 2018 Jun; 70(6):832-840. PubMed ID: 29439289 [TBL] [Abstract][Full Text] [Related]
34. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR; Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564 [TBL] [Abstract][Full Text] [Related]
35. Current evidence on the use of the adalimumab biosimilar SB5 (Imraldi Gisbert JP; Gaffney K; Young D; Ebbers HC; Girolomoni G Expert Opin Biol Ther; 2022 Feb; 22(2):109-121. PubMed ID: 34918591 [TBL] [Abstract][Full Text] [Related]
36. Usability and safety of SB5 (an adalimumab biosimilar) prefilled syringe and autoinjector in patients with rheumatoid arthritis. Ghil J; Zielińska A; Lee Y Curr Med Res Opin; 2019 Mar; 35(3):497-502. PubMed ID: 30561229 [TBL] [Abstract][Full Text] [Related]
37. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy. Tursi A; Mocci G; Cuomo A; Ferronato A; Elisei W; Picchio M; Maconi G; Scaldaferri F; Papa A; ; Allegretta L; Aragona G; Bianco MA; Colucci R; Della Valle N; Faggiani R; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Pica R; Pranzo G; Rodino' S; Sacco R; Sebkova L; Scarcelli A; Serio M; Napolitano D; Pugliese D; Schiavoni E; Turchini L; Armuzzi A; Zampaletta C J Gastrointestin Liver Dis; 2022 Dec; 31(4):411-416. PubMed ID: 36535057 [TBL] [Abstract][Full Text] [Related]
38. Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study. Fautrel B; Bouhnik Y; Salliot C; Carbonnel F; Fumery M; Bernardeau C; Maugars Y; Flamant M; Coury F; Braithwaite B; Hateb S; Addison J; Drugs Real World Outcomes; 2024 Dec; 11(4):573-591. PubMed ID: 39384685 [TBL] [Abstract][Full Text] [Related]
39. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Fischer S; Cohnen S; Klenske E; Schmitt H; Vitali F; Hirschmann S; Ramming A; Zundler S; Rath T; Krebs S; Dörje F; Uter W; Nagore D; Meyer S; Neurath MF; Atreya R Therap Adv Gastroenterol; 2021; 14():1756284820982802. PubMed ID: 33505519 [TBL] [Abstract][Full Text] [Related]
40. OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis. Maccora I; Lombardi N; Crescioli G; Bettiol A; Bonaiuti R; Pagnini I; Maniscalco V; Marrani E; Mastrolia MV; Ravaldi C; Consolini R; Cattalini M; Vannacci A; Simonini G Rheumatology (Oxford); 2022 Apr; 61(4):1518-1528. PubMed ID: 34273158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]